CERAMENT® G AND CERAMENT® V contributes to improved survival rates
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Mid Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
BONESUPPORT™, a leading company in orthobiologics for the management of bone injuries, today announces strong study results for CERAMENT G and CERAMENT V in the surgical treatment of bone infection due to diabetic foot ulcers. The study is the first to document that surgical treatment with antibiotic eluting CERAMENT has contributed to increased survival rates over a 5-year period.
The published clinical study included 105 patients with diabetic foot osteomyelitis that were either treated with surgical conventional treatment or surgical treatment including CERAMENT G or CERAMENT V. The results regarding infection healing, residual infection, re-infection, amputation, and mortality all showed significant advantages for the antibiotic eluting CERAMENT compared to standard treatment.
The pioneering finding of the study was the dramatic improvement in 5-year survival within the CERAMENT group: 87.5%, compared to 44.9% in the standard treatment group [Mortality rate 12,5%, vs 55.1%, p<0.00001].
"By including the antibiotic eluting CERAMENT G and CERAMENT V in surgical treatment, we have improved infection statistics and dramatically reduced the risk of major amputations and mortality. Our hospital now uses antibiotic eluting CERAMENT as the standard treatment for diabetic foot," said Professor Anand Pillai, orthopedic and trauma surgeon at Manchester University Hospital and principal investigator of the study.